SAN DIEGO, June 15, 2021 /PRNewswire/ -- Prometheus Laboratories, Inc. ("Prometheus"), a leader in precision healthcare, announces the execution of an agreement with MultiPlan, a trusted partner to ...

Prometheus Laboratories has been a leader in IBD patient care solutions for 30 years. Our continuum of tests empowers providers to diagnose, treat and help get IBD patients into remission faster with ...

The San Diego-based pharmaceutical company Prometheus Laboratories has launched PROMETHEUS Anser VDZ, a monitoring test for inflammatory bowel disease patients using vedolizumab. 1. The PROMETHEUS ...

PredictrPK® IFX influenced changes in care in 58% of cases and confirmed current treatment approach in the remaining 42% SAN DIEGO, CA / ACCESSWIRE / December 21, 2023 / Prometheus Laboratories Inc. ( ...

Prometheus Biosciences contends that the current treatments for inflammatory bowel disease are inadequate, taking a “one-size-fits-all approach” that doesn’t account for biologic variation. The ...

SAN DIEGO, July 31, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new generation monitoring ...

SAN DIEGO, CA / ACCESS Newswire / December 8, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision-guided medicine, announces the launch of IBD Precis ™, a next-generation ...

SAN DIEGO, Sept. 14, 2022 /PRNewswire/ -- Prometheus Laboratories Inc. ("Prometheus") today announced its partnership with Takeda Pharmaceutical Company Limited ("Takeda") to nationally launch CDPATH, ...

NEW YORK, Nov 7 (Reuters) - Privately held Prometheus Laboratories Inc said on Wednesday it has agreed to acquire exclusive U.S. rights to GlaxoSmithKline's irritable bowel syndrome drug Lotronex.